CN112852704A - 一种黑皮鸡枞菌多糖orp-1在肠道菌的增殖及黏附中的应用 - Google Patents
一种黑皮鸡枞菌多糖orp-1在肠道菌的增殖及黏附中的应用 Download PDFInfo
- Publication number
- CN112852704A CN112852704A CN202110166877.8A CN202110166877A CN112852704A CN 112852704 A CN112852704 A CN 112852704A CN 202110166877 A CN202110166877 A CN 202110166877A CN 112852704 A CN112852704 A CN 112852704A
- Authority
- CN
- China
- Prior art keywords
- intestinal
- orp
- polysaccharide
- proliferation
- adhesion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000004676 glycans Chemical class 0.000 title claims abstract description 64
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 64
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 64
- 102100025924 Oxysterol-binding protein-related protein 1 Human genes 0.000 title claims abstract description 62
- 101710201617 Oxysterol-binding protein-related protein 1 Proteins 0.000 title claims abstract description 62
- 230000000968 intestinal effect Effects 0.000 title claims abstract description 53
- 241001327916 Termitomyces albuminosus Species 0.000 title claims abstract description 41
- 230000035755 proliferation Effects 0.000 title claims abstract description 31
- 241000894006 Bacteria Species 0.000 title claims abstract description 9
- 241000588724 Escherichia coli Species 0.000 claims abstract description 43
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 42
- 239000006041 probiotic Substances 0.000 claims abstract description 23
- 235000018291 probiotics Nutrition 0.000 claims abstract description 23
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 claims abstract description 20
- 244000052616 bacterial pathogen Species 0.000 claims abstract description 20
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 17
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 17
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 12
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 30
- 238000004220 aggregation Methods 0.000 claims description 13
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 abstract description 35
- 241001237975 Termitomyces Species 0.000 abstract description 15
- 238000000338 in vitro Methods 0.000 abstract description 5
- 230000032677 cell aging Effects 0.000 abstract description 3
- 238000004088 simulation Methods 0.000 abstract description 3
- 238000012404 In vitro experiment Methods 0.000 abstract description 2
- 238000003501 co-culture Methods 0.000 abstract description 2
- 210000002919 epithelial cell Anatomy 0.000 abstract description 2
- 210000000813 small intestine Anatomy 0.000 abstract description 2
- 239000001963 growth medium Substances 0.000 description 27
- 230000000694 effects Effects 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 241000222680 Collybia Species 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 230000000529 probiotic effect Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 238000012258 culturing Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 238000002386 leaching Methods 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 235000013406 prebiotics Nutrition 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000003794 Gram staining Methods 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- VBIXEXWLHSRNKB-UHFFFAOYSA-N ammonium oxalate Chemical compound [NH4+].[NH4+].[O-]C(=O)C([O-])=O VBIXEXWLHSRNKB-UHFFFAOYSA-N 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229960001701 chloroform Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000004609 intestinal homeostasis Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Cosmetics (AREA)
Abstract
本发明公开了一种黑皮鸡枞菌多糖ORP‑1在肠道菌的增殖及黏附中的应用,以所述黑皮鸡枞菌多糖ORP‑1制备肠道菌群调节剂。本发明通过体外实验探讨黑皮鸡枞菌多糖ORP‑1对肠道益生菌和肠道条件性病原菌的增殖、黏附的影响,同时利用Caco‑2细胞体外模拟建立经D‑gal诱导的小肠上皮细胞衰老模型,将双歧杆菌BB、嗜酸乳杆菌LA及大肠杆菌EC分别与Caco‑2细胞以及经D‑gal诱导的Caco‑2细胞共培养。结果发现,黑皮鸡枞菌多糖ORP‑1可以促进双歧杆菌BB和嗜酸乳杆菌LA的增殖及在D‑gal诱导的Caco‑2细胞上黏附与定植,抑制肠道条件性病原菌大肠杆菌EC的增殖及在在D‑gal诱导的Caco‑2细胞上黏附与定植。
Description
技术领域
本发明属于肠道菌群调节剂技术领域,具体涉及一种黑皮鸡枞菌多糖ORP-1在肠道菌的增殖及黏附中的应用。
技术背景
益生菌是人体肠道内正常的生理性有益菌,双歧杆菌和嗜酸乳杆菌作为肠道内主要的益生菌,是通过在肠道内的黏附定植发挥益生作用。益生菌对肠道上皮细胞的黏附作用有利于其在肠道定植,从而恢复或增强肠道稳态,提高机体免疫力。而大肠杆菌作为人体肠道内条件性病原菌,异常时,大肠杆菌等条件性病原菌会大量增殖,损害肠道粘膜从而引发一些炎症,打破肠道稳态从而造成肠道紊乱。本发明通过间接和直接测定法来评价益生菌和条件性病原菌的黏附。间接测定法是指通过检测益生菌和条件性病原菌细胞壁的物理化学性质来推测黏附能力,比如疏水性、自聚集能力等。直接测定法是利用Caco-2细胞体外模拟建立经D-gal诱导的小肠上皮细胞衰老模型,通过革兰氏染色法直观地观察益生菌和条件性病原菌的黏附情况。
黑皮鸡枞菌多糖ORP-1是以黑皮鸡枞菌为原料制备的一种生物大分子。目前对于黑皮鸡枞菌多糖ORP-1的研究集中在结构和体外消化酵解的益生元活性上,而对于黑皮鸡枞菌多糖ORP-1促进肠道益生菌的黏附及抑制条件性病原菌的增殖和黏附尚未研究,同时在本研究中以已知益生元低聚果糖FOS作为阳性对照。
发明内容
本发明旨在提供一种黑皮鸡枞菌多糖ORP-1在肠道菌的增殖及黏附中的应用。本发明首次将黑皮鸡枞菌多糖经分离纯化得到的单一组分多糖ORP-1应用于肠道益生菌和肠道条件性病原菌致病菌的增殖与黏附实验,使得对黑皮鸡枞菌多糖的肠道菌群调节功能研究更具有靶向性。
所述黑皮鸡枞菌多糖ORP-1的组分构成以及制备方法为本课题组的前期研究工作,具体参见CN 110627919A公开的一种肠道益生元黑皮鸡枞菌多糖ORP-1及其制备方法和用途。
本发明黑皮鸡枞菌多糖ORP-1的应用,是以所述黑皮鸡枞菌多糖ORP-1制备肠道菌群调节剂。
所述肠道菌为肠道益生菌两歧双歧杆菌(Bifidobacterium bifidum,BB)、嗜酸乳杆菌(Lacrobacillus acidophilus,LA)及肠道条件性病原菌大肠杆菌(Escherichiacoli,EC)。
所述肠道菌群调节剂能够促进肠道益生菌双歧杆菌BB和嗜酸乳杆菌LA的增殖,提高双歧杆菌BB和嗜酸乳杆菌LA的疏水性及自聚集能力,提高双歧杆菌BB和嗜酸乳杆菌LA对D-gal诱导的Caco-2细胞的黏附率。
所述肠道菌群调节剂能够抑制肠道条件性病原菌大肠杆菌EC的增殖,降低大肠杆菌EC疏水性及自聚集能力,降低大肠杆菌EC对D-gal诱导的Caco-2细胞的黏附率。
本发明通过体外实验探讨黑皮鸡枞菌多糖ORP-1对肠道益生菌和肠道条件性病原菌的增殖、疏水性和自凝集能力的影响,同时利用Caco-2细胞体外模拟建立经D-gal诱导的小肠上皮细胞衰老模型,将双歧杆菌BB、嗜酸乳杆菌LA及大肠杆菌EC分别与Caco-2细胞以及经D-gal诱导的Caco-2细胞共培养。在体外增殖的实验中,以FOS为阳性对照。结果发现,黑皮鸡枞菌多糖ORP-1可以促进双歧杆菌BB和嗜酸乳杆菌LA的增殖及在D-gal诱导的Caco-2细胞上黏附与定植,抑制肠道条件性病原菌大肠杆菌EC的增殖及在D-gal诱导的Caco-2细胞上黏附与定植。综合考虑黑皮鸡枞菌多糖ORP-1的增殖效果不次于FOS,也适于作为一种新型的肠道调节剂,所以在接下来的黏附操作中仅考察我们黑皮鸡枞菌多糖ORP-1的黏附作用即可。具体过程如下:
(一)本发明黑皮鸡枞菌多糖ORP-1应用于肠道益生菌双歧杆菌BB和嗜酸乳杆菌LA的增殖及黏附:
1、所述黑皮鸡枞菌多糖ORP-1制备方法参考申请者课题组前期公布号为CN110627919A的发明专利。
2、将双歧杆菌BB和嗜酸乳杆菌LA分别以2%的接种量接种于MRS培养基中。
3、将步骤1制备的黑皮鸡枞菌多糖ORP-1分别加入到步骤2所得的MRS培养基中,使其终浓度为2%,阳性对照组为添加了2%的FOS的MRS培养基,空白对照组为未添加黑皮鸡枞菌多糖ORP-1的空白MRS培养基。
4、将步骤3所得培养基同时置于培养箱,于37℃厌氧培养18-24h,用于增殖、疏水性和自凝聚能力应用。
5、将1mL菌体浓度为5.0×109CFU/mL的双歧杆菌和嗜酸乳杆菌分别加入到Caco-2细胞以及经D-gal诱导的Caco-2细胞中。
6、取1mL用DMEM高糖培养基配制的浓度为1600μg/mL的黑皮鸡枞菌多糖ORP-1分别添加于步骤5所得Caco-2细胞中使其终浓度为800μg/mL,并粘附2h,用于粘附应用。
(二)本发明黑皮鸡枞菌多糖ORP-1应用于肠道条件性病原菌大肠杆菌EC的增殖及黏附:
1、所述黑皮鸡枞菌多糖ORP-1制备方法参考申请者课题组前期公布号为CN110627919A的发明专利。
2、将大肠杆菌EC以2%的接种量接种于LB培养基中。
3、将步骤1制备的黑皮鸡枞菌多糖ORP-1分别加入到步骤2所得的LB培养基中,使其终浓度为2%,阳性对照组为添加了2%的FOS的LB培养基,空白对照组为未添加黑皮鸡枞菌多糖ORP-1的空白LB培养基。
4、将步骤3所得培养基同时置于培养箱,于37℃厌氧培养18-24h,用于增殖、疏水性和自凝聚能力应用。
5、将1mL菌体浓度为5.0×109CFU/mL大肠杆菌分别加入到Caco-2细胞以及经D-gal诱导的Caco-2细胞中。
6、取1mL用DMEM高糖培养基配制的浓度为1600μg/mL的黑皮鸡枞菌多糖ORP-1分别添加于步骤5所得Caco-2细胞中使其终浓度为800μg/mL,并粘附2h,用于粘附应用。
本发明的有益效果体现在:
本发明中的肠道菌群调节剂黑皮鸡枞菌多糖ORP-1可以促进肠道益生菌双歧杆菌BB和嗜酸乳杆菌LA的增殖,提高双歧杆菌BB和嗜酸乳杆菌LA的疏水性及自聚集能力,提高双歧杆菌BB和嗜酸乳杆菌LA对D-gal诱导的Caco-2细胞的黏附率;本发明中的肠道菌群调节剂黑皮鸡枞菌多糖ORP-1可以抑制肠道条件性病原菌大肠杆菌EC的增殖,降低大肠杆菌EC疏水性及自聚集能力,降低大肠杆菌EC对D-gal诱导的Caco-2细胞的黏附率。
附图说明
图1为本发明实施例2中黑皮鸡枞菌多糖ORP-1和FOS对双歧杆菌BB、嗜酸乳杆菌LA和大肠杆菌EC增殖的影响。从图中可知,黑皮鸡枞菌多糖ORP-1和FOS干预后,能够明显促进肠道益生菌双歧杆菌BB和嗜酸乳杆菌LA的增殖,抑制肠道条件性病原菌大肠杆菌EC的增殖。在0-16h内,ORP-1对BB的促进作用优于FOS;在13-24h内,ORP-1对LA的促进作用优于FOS;在0-24h内,ORP-1对EC的抑制作用优于FOS。
图2为本发明实施例3中黑皮鸡枞菌多糖ORP-1对双歧杆菌BB、嗜酸乳杆菌LA和大肠杆菌EC疏水性的影响。结果显示,黑皮鸡枞菌多糖ORP-1明显提高了双歧杆菌BB和嗜酸乳杆菌LA的疏水性,降低了大肠杆菌EC的疏水性。
图3为本发明实施例4中黑皮鸡枞菌多糖ORP-1对双歧杆菌BB、嗜酸乳杆菌LA和大肠杆菌EC自聚集能力的影响。从图中看出,黑皮鸡枞菌多糖ORP-1明显提高双歧杆菌BB和嗜酸乳杆菌LA的自聚集能力,降低大肠杆菌EC的自聚集能力。
图4为本发明实施例5中800μg/mL黑皮鸡枞菌多糖ORP-1对双歧杆菌BB(A)、嗜酸乳杆菌LA(B)和大肠杆菌EC(C)黏附Caco-2细胞的影响。结果显示,D-gal诱导后,双歧杆菌BB和嗜酸乳杆菌LA对Caco-2细胞黏附能力显著性降低,大肠杆菌EC对Caco-2细胞黏附能力显著性升高;800μg/mL黑皮鸡枞菌多糖ORP-1干预D-gal诱导的Caco-2细胞后,能够显著提高双歧杆菌BB和嗜酸乳杆菌LA对Caco-2细胞的黏附率,降低大肠杆菌EC对Caco-2细胞的黏附率。
具体实施方式
实施例1:
本实施例肠道菌群调节剂为黑皮鸡枞菌多糖ORP-1,其制备步骤参考申请者课题组前期公布号为CN 110627919 A的发明专利。
黑皮鸡枞菌子实体经粉碎过60目筛,热水浸提三次得浸提液,浸提液与无水乙醇按照1:4的比例醇沉,所得的沉淀物用蒸馏水溶解即得黑皮鸡枞菌粗多糖水溶液。用Sevage法按照多糖水溶液:三氯甲烷:正丁醇=5:4:1除蛋白,醇沉之后冻干即得黑皮鸡枞菌粗多糖。将黑皮鸡枞菌粗多糖过DEAE-52纤维素层析柱和Superdex-75分子筛凝胶层析柱后即得黑皮鸡枞菌多糖ORP-1。
实施例2:
实施例1中获得的黑皮鸡枞菌多糖ORP-1和FOS对肠道益生菌双歧杆菌BB和嗜酸乳杆菌LA及肠道条件性病原菌大肠杆菌EC增殖的影响
将双歧杆菌BB和嗜酸乳杆菌LA分别以2%的接种量接入含有蛋白胨10g/L,牛肉膏10g/L,酵母膏5g/L,无水葡萄糖20g/L,吐温-80 1mL/L,磷酸氢二钾2g/L,乙酸钠5g/L,柠檬酸氢二铵2g/L,硫酸镁0.58g/L,硫酸锰0.25g/L的MRS培养基中,随后往MRS培养基中加入黑皮鸡枞菌多糖ORP-1使其浓度为2%,阳性对照组为添加了2%的FOS的MRS培养基,空白对照组为未添加黑皮鸡枞菌多糖ORP-1的空白MRS培养基。置于厌氧培养箱37℃培养24h,每隔4h测定培养液OD600值监测双歧杆菌和嗜酸乳杆菌的增殖情况。
将大肠杆菌以2%的接种量接入到牛肉膏3g/L,蛋白胨10g/L,氯化钠5g/L的LB培养基中,随后往LB培养基中加入黑皮鸡枞菌多糖ORP-1使其浓度为2%,阳性对照组为添加了2%的FOS的LB培养基,空白对照组为未添加黑皮鸡枞菌多糖ORP-1的空白LB培养基。置于厌氧培养箱37℃培养24h,每隔4h测定培养液OD600值监测大肠杆菌的增殖情况。
实施例3:
实施例1中获得的黑皮鸡枞菌多糖ORP-1对肠道益生菌双歧杆菌BB和嗜酸乳杆菌LA及肠道条件性病原菌大肠杆菌EC疏水性的影响
将双歧杆菌和嗜酸乳杆菌分别以2%的接种量接种于MRS培养基中,大肠杆菌以2%的接种量接种于LB培养基中,随后往MRS和LB培养基中分别加入黑皮鸡枞菌多糖ORP-1使其终浓度为2%,对照组为未添加黑皮鸡枞菌多糖ORP-1的空白MRS和LB培养基。于37℃厌氧培养18h,以6000r/min于4℃离心10min,弃上清,收集菌体沉淀。用无菌PBS溶液(pH=7.2)洗涤菌体沉淀2次后,将菌体重悬于PBS中使待测菌悬液吸光度为OD600=0.25±0.05。分别取3mL双歧杆菌、嗜酸乳杆菌和大肠杆菌待测菌悬液加入等体积的二甲苯,对照组不加,漩涡震荡3min,室温静置60min(此时实验组形成两相体系),吸取水相测定OD600(A1),A0为对照组在600nm的水相吸光值。
疏水率(%)=[(A0-A1)/A0]×100
实施例4:
实施例1中获得的黑皮鸡枞菌多糖ORP-1对肠道益生菌双歧杆菌BB和嗜酸乳杆菌LA及肠道条件性病原菌大肠杆菌EC自凝聚能力的影响
将双歧杆菌BB和嗜酸乳杆菌LA分别以2%的接种量接种于MRS培养基中,大肠杆菌EC以2%的接种量接种于LB培养基中,随后往MRS和LB培养基中分别加入黑皮鸡枞菌多糖ORP-1使其终浓度为2%,对照组为未添加黑皮鸡枞菌多糖ORP-1的空白MRS和LB培养基,于37℃培养18h,以6000r/min于4℃离心10min,弃上清,收集菌体沉淀。用无菌PBS溶液(pH=7.2)洗涤2次后,将菌体重悬于PBS中待用。分别取2mL双歧杆菌、嗜酸乳杆菌和大肠杆菌待测菌悬液于试管中漩涡震荡1min,测定OD600(A0),于37℃静置2h,吸取1mL上清液测定OD600(At)。
自凝聚率(%)=[(A0-At)/A0]×100
实施例5:
实施例1中获得的黑皮鸡枞菌多糖ORP-1对肠道益生菌双歧杆菌BB、嗜酸乳杆菌LA及肠道条件性病原菌大肠杆菌EC黏附Caco-2细胞的影响
将1mL菌体浓度为5.0×109CFU/mL的双歧杆菌、嗜酸乳杆菌和大肠杆菌分别加入到Caco-2细胞以及经D-gal诱导的Caco-2细胞中,同时加入1mL用DMEM高糖培养基配制的浓度为1600μg/mL的黑皮鸡枞菌多糖ORP-1,使其终浓度为800μg/mL,共培养2h后,用革兰氏染色法观察益生菌和大肠杆菌的黏附情况。
革兰氏染色法采用如下步骤:先用PBS洗去尚未黏附的菌落,用4%的多聚甲醛固定30min后,草酸铵结晶紫染1分钟,蒸馏水冲洗,加碘液覆盖涂面染约1分钟,水洗,用吸水纸吸去水分,加95%酒精数滴,并轻轻摇动进行脱色,20秒后水洗,吸去水分,蕃红染色液(稀)染1分钟后,蒸馏水冲洗,干燥,于倒置显微镜下观察双歧杆菌、嗜酸乳杆菌和大肠杆菌的黏附情况。
Claims (4)
1.一种黑皮鸡枞菌多糖ORP-1在肠道菌的增殖及黏附中的应用,其特征在于:
以所述黑皮鸡枞菌多糖ORP-1制备肠道菌群调节剂。
2.根据权利要求1所述的应用,其特征在于:
所述肠道菌为肠道益生菌两歧双歧杆菌、嗜酸乳杆菌及肠道条件性病原菌大肠杆菌。
3.根据权利要求2所述的应用,其特征在于:
所述肠道菌群调节剂能够促进肠道益生菌双歧杆菌BB和嗜酸乳杆菌LA的增殖,提高双歧杆菌BB和嗜酸乳杆菌LA的疏水性及自聚集能力,提高双歧杆菌BB和嗜酸乳杆菌LA对D-gal诱导的Caco-2细胞的黏附率。
4.根据权利要求2所述的应用,其特征在于:
所述肠道菌群调节剂能够抑制肠道条件性病原菌大肠杆菌EC的增殖,降低大肠杆菌EC疏水性及自聚集能力,降低大肠杆菌EC对D-gal诱导的Caco-2细胞的黏附率。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110166877.8A CN112852704B (zh) | 2021-02-05 | 2021-02-05 | 一种黑皮鸡枞菌多糖orp-1在肠道菌的增殖及黏附中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110166877.8A CN112852704B (zh) | 2021-02-05 | 2021-02-05 | 一种黑皮鸡枞菌多糖orp-1在肠道菌的增殖及黏附中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112852704A true CN112852704A (zh) | 2021-05-28 |
CN112852704B CN112852704B (zh) | 2023-04-04 |
Family
ID=75988861
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110166877.8A Active CN112852704B (zh) | 2021-02-05 | 2021-02-05 | 一种黑皮鸡枞菌多糖orp-1在肠道菌的增殖及黏附中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112852704B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116178579A (zh) * | 2023-02-20 | 2023-05-30 | 西南医科大学 | 一种黑皮鸡枞菌多糖及其制备方法与应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101189982A (zh) * | 2006-11-27 | 2008-06-04 | 郑慧娣 | 含有海藻多糖和双歧杆菌的酸奶 |
CN101724089A (zh) * | 2009-09-23 | 2010-06-09 | 南京大学 | 酸性芦荟多糖及其制备纯化方法和应用 |
CN102451221A (zh) * | 2010-10-15 | 2012-05-16 | 佳木斯大学 | 黄芪多糖微生态调节剂 |
CN102697845A (zh) * | 2010-10-15 | 2012-10-03 | 佳木斯大学 | 复方多糖中药微生态调节剂 |
CN103053904A (zh) * | 2012-12-29 | 2013-04-24 | 北京中科邦尼国际科技有限责任公司 | 一种具有调节肠道菌群功能的复合功能糖 |
CN110628702A (zh) * | 2019-10-17 | 2019-12-31 | 武汉轻工大学 | 人体肠道上皮细胞模型的构建方法 |
CN110627919A (zh) * | 2019-11-06 | 2019-12-31 | 安徽大学 | 一种肠道益生元黑皮鸡枞菌多糖orp-1及其制备方法和用途 |
-
2021
- 2021-02-05 CN CN202110166877.8A patent/CN112852704B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101189982A (zh) * | 2006-11-27 | 2008-06-04 | 郑慧娣 | 含有海藻多糖和双歧杆菌的酸奶 |
CN101724089A (zh) * | 2009-09-23 | 2010-06-09 | 南京大学 | 酸性芦荟多糖及其制备纯化方法和应用 |
CN102451221A (zh) * | 2010-10-15 | 2012-05-16 | 佳木斯大学 | 黄芪多糖微生态调节剂 |
CN102697845A (zh) * | 2010-10-15 | 2012-10-03 | 佳木斯大学 | 复方多糖中药微生态调节剂 |
CN103053904A (zh) * | 2012-12-29 | 2013-04-24 | 北京中科邦尼国际科技有限责任公司 | 一种具有调节肠道菌群功能的复合功能糖 |
CN110628702A (zh) * | 2019-10-17 | 2019-12-31 | 武汉轻工大学 | 人体肠道上皮细胞模型的构建方法 |
CN110627919A (zh) * | 2019-11-06 | 2019-12-31 | 安徽大学 | 一种肠道益生元黑皮鸡枞菌多糖orp-1及其制备方法和用途 |
Non-Patent Citations (6)
Title |
---|
孙凯等: "双正交法优化醇洗-水提黑皮鸡枞菌多糖的研究", 《食品工程》 * |
彭珍等: "益生菌和致病菌对肠道的黏附及其相互作用研究进展", 《中国微生态学杂志》 * |
徐兵等: "超声波法提取黑皮鸡枞多糖工艺优化研究", 《食品研究与开发》 * |
朱艳等: "果蔬发酵汁对肠道益生菌及大肠杆菌黏附能力的影响", 《食品科技》 * |
李清等: "植物乳杆菌表面性质及对Caco-2细胞的黏附", 《食品科学》 * |
陈文宁等: "海带多糖的免疫作用研究进展及其在养猪生产上的应用", 《黑龙江畜牧兽医》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116178579A (zh) * | 2023-02-20 | 2023-05-30 | 西南医科大学 | 一种黑皮鸡枞菌多糖及其制备方法与应用 |
Also Published As
Publication number | Publication date |
---|---|
CN112852704B (zh) | 2023-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104928208B (zh) | 一种植物乳杆菌Lp90及其筛选方法和应用 | |
AU2011230685A1 (en) | Anti-allergic agent | |
CN111534455B (zh) | 一种乳酸杆菌溶孢产物的制备及其在化妆品的应用 | |
CN111534435B (zh) | 一种可提高双歧杆菌耐酸性的冻干保护剂及其应用 | |
CN109453207B (zh) | 一种硒化海藻酸钠与硒化壳聚糖包覆的益生菌双层微胶囊、制备方法及其应用 | |
CN111920048B (zh) | 一种含有玫瑰发酵液的胶囊及其制备方法 | |
CN113773984B (zh) | 提高黄精多糖得率并调节皮肤屏障与免疫的鼠李糖乳杆菌 | |
CN112852704B (zh) | 一种黑皮鸡枞菌多糖orp-1在肠道菌的增殖及黏附中的应用 | |
CN111820419A (zh) | 靶向调控肠道艾克曼菌和短链脂肪酸产生菌的组合物 | |
CN112063679A (zh) | 一种混合益生菌发酵复合碳水化合物制备短链脂肪酸的方法 | |
CN111713685A (zh) | 一种微胶囊壁材及其在制备益生菌微胶囊中的应用 | |
CN113215047B (zh) | 魔芋多糖降解产物KGM-1k与KGM-5k在制备益生菌保护剂中的应用 | |
CN104231106B (zh) | 一种类芽孢杆菌的胞外多糖、制备方法及其应用 | |
CN112626148B (zh) | 一种合生元的制备方法 | |
CN108095077B (zh) | 一种利用益生菌制备竹笋酵素粉的方法 | |
CN114606280B (zh) | 一种合生元组合物及其制备方法 | |
CN112869172A (zh) | 一种具有益生菌特异性的微胶囊壁材及其制备方法与应用 | |
WO2021068770A1 (zh) | 一种低糖的益生组合物及其制备方法和应用 | |
CN115354009B (zh) | 一种具有菌毛的长双歧杆菌婴儿亚种及其应用 | |
CN116574664A (zh) | 长双歧杆菌胞外多糖在促进乳酸菌增殖方面的应用 | |
CN113278549B (zh) | 一株蜡样芽孢杆菌及其应用 | |
CN113151071B (zh) | 一株贝莱斯芽孢杆菌及其应用 | |
CN112501049B (zh) | 产转糖基活性β-半乳糖苷酶的开菲尔乳杆菌及制备的β-半乳糖苷酶生产低聚半乳糖的方法 | |
JP4057617B2 (ja) | 酢酸菌型セラミドの製造方法 | |
CN114525221A (zh) | 一种提高益生菌耐受性的方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |